Related Experiment Video
Updated: Dec 13, 2025

06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
15.4K
PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing
Anna Pia Enblad1, Oskar Bergengren1, Ove Andrén2
1Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Scandinavian Journal of Urology
|August 1, 2020
Summary
Opportunistic prostate-specific antigen (PSA) testing was common in Sweden before organized programs. Repeat testing occurred frequently, even with low PSA levels, particularly in older men not targeted for organized screening.
Area of Science:
- Urology
- Public Health
- Cancer Screening
Background:
- Sweden is implementing organized prostate-specific antigen (PSA) testing for men aged 50-74.
- This initiative aims to reduce opportunistic testing in individuals unlikely to benefit.
- Understanding current opportunistic testing patterns is crucial for this transition.
Purpose of the Study:
- To describe opportunistic PSA testing patterns in a Swedish region prior to organized screening implementation.
- To analyze PSA testing frequency and outcomes in a defined population.
Main Methods:
- A cohort (UPSAC) was created from men PSA tested in the Uppsala-Örebro region (2012-2014).
- Data on prior testing, diagnoses, and demographics were sourced from population registries.
- Men were categorized into single and repeat PSA testers.
Main Results:
- 18.1% of the adult male population underwent PSA testing; 21% of men over 85 were tested.
- 62.1% of tested men were repeat testers, with 53.8% of those having low PSA levels (≤1µg/l).
- Prostate cancer detection rates were 2.7% for repeat testers and 4.8% for single testers.
Conclusions:
- PSA testing was prevalent, with repeat testing common even at low PSA levels.
- Frequent repeat testing, especially in older men, suggests a need for targeted interventions.
- Current patterns highlight the importance of shifting towards organized, evidence-based PSA screening.

